03Jun/13

Remote monitoring cost-effective for heart failure patients with implantable … – FierceMobileHealthcare (press release)

Remote monitoring cost-effective for heart failure patients with implantable
FierceMobileHealthcare (press release)
Remote management of heart failure patients with implantable defibrillators appears to be cost-effective compared to the conventional method of in-person evaluations, finds an article in the Journal of Medical Internet Research. “Heart failure patients

03Jun/13

Under One Roof: Roche Talks Up In-House Advantages In Cancer – The IN VIVO Blog (blog)


The IN VIVO Blog (blog)

Under One Roof: Roche Talks Up In-House Advantages In Cancer
The IN VIVO Blog (blog)
That’s what Roche is looking to do in hematology, moving from the rituximab base to new drugs like GA101. “We have a number of scenarios that can help us both extend the franchise and potentially replace and extend the franchise,” Roche Pharma COO

03Jun/13

ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of … – The Herald | HeraldOnline.com

ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of
The Herald | HeraldOnline.com
“We are encouraged by the evidence of antitumor activity of IGN002 observed in pre-clinical studies in rituximab-resistant tumor models and are preparing for an IND filing for IGN002 in the second half of 2014.” About IGN002. IGN002, a fusion molecule

and more »